Szoke et al. recently reported on the use of nucleoside modified VEGF-C mRNA delivered using lipid nanoparticles to promote organ-specific lymphangiogenesis and treat experimentally induced lymphedema. This evidence concerns the gene VEGFC and lymphedema.